Fujilai released its 2026 interim report. First-half operating revenue was 185 million yuan, down 17.2% year on year, with a loss of 14.62 million yuan, down 133.9% year on year. Excluding non-recurring items, the loss was 20.07 million yuan, down 380.2% year on year. Net operating cash flow was negative 26.74 million yuan, down 154.9% year on year, and earnings per share were negative 0.165 yuan. Second-quarter operating revenue was 92.61 million yuan, down 16.4% year on year, and net profit attributable to the parent company showed a loss of 11.85 million yuan, down 161.9% year on year. The company said the decline was mainly affected by overseas market inflation and reduced customer demand. Alpha-lipoic acid series products account for a relatively high share of revenue, and there is a risk from changes in the market environment.
Suzhou Fushilai Pharmaceutical Co. Ltd.First-half loss of 14.62 million yuan, down 133.9% year on year, with revenue down 17.2%.
